Prime Medicine, Inc.
Assessment
Our Rating
A journalistic assessment by our editorial team at the time of the deep dive — it rates the company, not the entry point. Not investment advice and not a solicitation to buy or sell.
We found at least one documented issue that threatens the company itself — regardless of how the stock is currently valued.
Why this colour
Red, because there is a documented substance risk: in its 2025 annual report and its quarterly report for the period ended June 30, 2026, Prime Medicine reports substantial doubt about its ability to continue as a going concern. At the first-half 2026 burn rate, its $95.1 million in cash lasts well under four quarters; without new stock, partner money or other financing it cannot continue. The scientific progress is real but does not change that position. The decision is yours.
What the thesis turns on
Assessment: Opportunities & Risks
Prime Medicine is a textbook case of the cure reflex: scientifically, the company is moving forward in 2026 — trial clearances for PM577a, a won arbitration, a planned marketing application for PM359. Financially, though, only $95.1 million sat in cash and investments as of June 30, 2026, the half-year cost $83.8 million, and the company reports substantial doubt about its ability to continue as a going concern. Without new financing, first liver data and the end of the existing cash fall into the same year. Not investment advice.
Liquidity & going concern
$95.1 million in cash and investments (06/30/2026) against $83.8 million of operating outflow in H1 2026; going-concern warning in the 2025 10-K and the 10-Q for the quarter ended 06/30/2026, cash lasts into 2027 per the company.
Pipeline & progress
Trial clearances for PM577a in New Zealand (06/2026) and the U.S. (07/2026), RMAT designation for PM359 (06/2026), PM359 marketing application planned for H1 2027.
Rights & patents
Arbitration award of 07/06/2026 in Prime Medicine’s favor against Beam; at the same time no issued patents of its own and dependence on the licensor Broad Institute (10-Q for the quarter ended 06/30/2026).
Costs
Headcount cut from 214 (12/31/2024) to 146 (12/31/2025); Q2 2026 net loss of $42.1 million versus $52.6 million a year earlier.
Dilution
Share count rose from 131.2 million to 180.5 million in 2025; $200 million registered under the at-the-market program, 26.0 million options and performance-based awards outstanding (06/30/2026).
Worth Noting
Prime Medicine made our research list through our in-house Reddit hype scanner.
Quarterly cash and investments summed from the 10-Q/10-K balance sheets (cash and cash equivalents plus short-term investments, through Q3 2025 including Beam shares held, excluding restricted cash).
Q2 2026 operating cash outflow ($41.0 million) as the difference between the half-year figure ($83.8 million, 10-Q for the quarter ended 06/30/2026) and the Q1 figure ($42.7 million, 10-Q for the quarter ended 03/31/2026).
Market value computed: 181,376,856 shares (10-Q cover, 07/31/2026) × $4.72 closing price (10/30/2026); the share count matches the fundamental data exactly. No SEC filing after 08/06/2026 through 10/31/2026.
The runway estimate (just under seven months from 06/30/2026) is our own rough calculation: $95.1 million divided by the average monthly outflow of H1 2026 ($83.8 million / 6).
Stock Watch
This analysis is as of October 31, 2026. Stock Watch will tell you what's changed at PRME since then.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 2.70 $ to 5.40 $ · Last price: 4.70 $ (As of: October 30, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 10/30/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Biotechnology
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| Prime Medicine, Inc. PRME | 0.9 | – | -3.1 | -3,489.5 | – | 55.3 | 15.4 |
| Vertex Pharmaceuticals Inc VRTX | 141.4 | 33.3 | 25.7 | 55.0 | 38.1 | 9.6 | 33.1 |
| Regeneron Pharmaceuticals Inc REGN | 96.4 | 23.4 | 13.1 | 44.5 | 20.7 | 1.0 | 42.6 |
| Moderna Inc MRNA | 88.0 | – | 4.6 | -66.0 | -131.1 | -39.2 | 687.9 |
| argenx NV ARGX | 55.5 | 34.1 | 26.2 | 59.8 | 32.0 | 89.6 | 8.8 |
| BeiGene, Ltd. ONC | 41.9 | 66.1 | 33.8 | 88.9 | 19.1 | 40.2 | 18.0 |
| Revolution Medicines Inc RVMD | 39.8 | – | -9.7 | -174,708.6 | 0.0 | -100.0 | 225.0 |
| Royalty Pharma Plc RPRX | 37.0 | 36.4 | 20.8 | 95.8 | 100.3 | 5.1 | 85.4 |
| Genmab AS GMAB | 35.6 | 44.9 | 24.7 | 93.0 | 35.2 | -82.7 | 99.0 |
| Median of companies shown | 41.9 | 35.2 | 20.8 | 55.0 | 26.3 | 5.1 | 42.6 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2019 | – | -2 | -3 | -0.03 | -1 | 1 | 9 |
| 2020 | 5 | -1 | -3 | -0.04 | -6 | 33 | 55 |
| 2021 | 0 | -84 | -165 | -1.73 | -34 | 240 | 302 |
| 2022 | 5 | -117 | -122 | -1.25 | -132 | 316 | 360 |
| 2023 | 0 | -205 | -198 | -2.18 | -165 | 133 | 194 |
| 2024 | 3 | -202 | -196 | -1.65 | -123 | 153 | 298 |
| 2025 | 5 | -208 | -201 | -1.35 | -163 | 121 | 343 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.31 | – | 2 | -91.50 | -1,936.60 | 16 | 15 |
| 2025: Q1 | -0.40 | – | 2 | 146.00 | -3,568.80 | -49 | -51 |
| 2025: Q2 | -0.41 | – | 1 | -97.00 | -4,716.70 | -41 | -43 |
| 2025: Q3 | -0.32 | – | 1 | 486.10 | -4,129.10 | -35 | -35 |
| 2025: Q4 | -0.31 | – | 1 | -61.60 | -5,498.70 | -37 | -38 |
| 2026: Q1 | -0.28 | – | 1 | -41.10 | -5,738.60 | -43 | -43 |
| 2026: Q2 | -0.24 | 41.50 | – | – | – | -41 | -41 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 7 of our scanner strategies — each hit links to the scanner.
Quality & Balance Sheet
Research
Risk & Weakness
- Bankruptcy Study: Stacked Warning Signals
- Insolvency Radar: Cash Running Low
- Stage 4 (Downtrend)
- Stan Weinstein: Stage 4
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.94 | -1.11 – -0.81 | 9 | 30.0% | 14 |
| 12/31/2027 | -0.89 | -1.22 – -0.67 | 11 | 6.0% | 12 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Free cash flow over the past twelve months is negative, which rules out a serious reverse calculation. Any growth rate only makes a negative cash flow more negative; no present value comes out of it. What the price reflects here is therefore not a stream of cash flows, but the expectation that there will be one at all.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Prime Medicine setzt laut Geschäftsbericht für 2024 maschinelles Lernen in der eigenen Forschung ein — eigene Algorithmen sagen die Wirksamkeit der Leit-RNA (pegRNA) voraus und helfen, effizientere und präzisere Prime Editors zu entwickeln —, verkauft aber keine KI und nennt KI nicht als konkrete Bedrohung des Geschäftsmodells. Geprüft am 31.10.2026 gegen die Quartalsberichte (10-Q) zum 30.06.2026, 31.03.2026, 30.09.2025 und 30.06.2025 sowie die Geschäftsberichte (10-K) für 2025 und 2024: Die vier Quartalsberichte erwähnen KI nicht; der Geschäftsbericht für 2025 spricht nur noch von „computational modeling“ und führt KI ansonsten als allgemeines Risiko — deshalb „nutzt“ auf Basis des 10-K 2024, nicht „verkauft“ oder „bedroht“.
View the full file — quotes, sources, reviewed filings
„In addition, our focus on high-throughput screening and machine learning are allowing us to grow our internal technical expertise for Prime Editing optimization and are being used to develop Prime Editors that are both more efficient and more precise."
Zudem ermöglichen uns Hochdurchsatz-Screening und maschinelles Lernen, unser internes technisches Know-how zur Optimierung von Prime Editing auszubauen; beides wird eingesetzt, um Prime Editors zu entwickeln, die sowohl effizienter als auch präziser sind.
10-K · 2025-02-28 · View SEC filing
„The data is also used to develop proprietary machine learning algorithms for pegRNA activity prediction."
Die Daten werden außerdem genutzt, um eigene Algorithmen des maschinellen Lernens zur Vorhersage der pegRNA-Aktivität zu entwickeln.
10-K · 2025-02-28 · View SEC filing
„Many of these workflows are automated to allow rapid machine learning and/or artificial intelligence-based data analysis, correlation, visualization, and iterative optimization and innovation."
Viele dieser Arbeitsabläufe sind automatisiert, um eine schnelle Datenanalyse, Korrelation, Visualisierung sowie iterative Optimierung und Innovation auf Basis von maschinellem Lernen und/oder künstlicher Intelligenz zu ermöglichen.
10-K · 2025-02-28 · View SEC filing
Filings Reviewed: 10-Q 2026-08-06 · 10-Q 2026-05-07 · 10-Q 2025-11-07 · 10-Q 2025-08-07 · 10-K 2026-03-03 · 10-K 2025-02-28
Rated on October 31, 2026 · How the Rating Is Built
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -3.8%
- More than 10% revenue growth is expected for the coming year 109.2%
- Share count grows by less than 3% a year 15.2%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -3,552.1%
- Gross margin at 40% or higher and without meaningful erosion no data
- Goodwill from acquisitions does not grow faster than revenue 0.0%
- Net debt below twice EBITDA 61 m net cash
- Operating cash flow covers the profits of the last three years 144 m
- Return on capital at 15% or higher, or up versus two years ago -68.3%
- Insiders hold at least 10% or are net buyers 23.8%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
4/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% -2.3%
- Exp. sales growth 3Y > 5% 51.3%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 51.3%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% -166.4%
- ROCE > 15% -68.2%
- Expected return > 10% 22.8%
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
The company
About the Company
Prime Medicine, Inc., ein Biotechnologieunternehmen, befasst sich mit der Bereitstellung genetischer Medizin zur Behandlung eines breiten Krankheitsspektrums durch den Einsatz von Gen-Editing-Technologie in den USA.
- Employees
- 146
- Headquarters
- Cambridge, MA
- Address
- 60 First Street, 02141 Cambridge, United States
- Phone
- 617 465 0013
- Website
- primemedicine.com
- IPO Date
- 10/20/2022
- ISIN
- US74168J1016
Management
| Name | Title | Birth Year |
|---|---|---|
| Jeffrey D. Marrazzo M.B.A., M.P.A. | Executive Chair | 1979 |
| Allan Reine M.D. | CEO & Director | 1975 |
| Ann L. Lee Ph.D. | Chief Technical Officer | 1962 |
| Andrew Anzalone M.D., Ph.D. | Co-Founder & Head of Platform | 1987 |
| David R. Liu Ph.D. | Co-Founder & Member of Scientific Advisory Board | – |
| Svetlana Makhni | Chief Financial Officer | 1984 |
| Ryan E. Brown J.D. | Chief Legal Officer | 1979 |
| Niamh Alix | Chief Human Resources Officer | – |
| Mohammed Asmal M.D., Ph.D. | Chief Medical Officer | – |
| Matthew J. Hawryluk M.B.A., Ph.D. | Chief Business Officer | 1979 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
Data as of: October 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.